超载的胞质游离 Ca 2+ (cCa 2+) 在病理生理条件下,内流介导的氧化应激过度产生通过激活阳离子通道诱导神经元和细胞损伤。TRPM2 和 TRPV4 通道被氧化应激激活,其特异性拮抗剂尚未被发现。最近报道了香芹酚 (CARV) 的抗氧化和抗 Covid-19 特性。因此,我怀疑 CARV 可能对神经元和肾细胞中的氧化应激 (OS)/ADP-核糖 (ADPR) 诱导的 TRPM2 和 GSK1016790A (GSK) 介导的 TRPV4 激活具有拮抗作用。我研究了 CARV 对 SH-SY5Y 神经元、BV-2 小胶质细胞和 HEK293 细胞中 TRPM2 和 TRPV4 激活的拮抗作用。细胞中的 OS/ADPR 和 GSK 导致 TRPM2/TRPV4 电流密度增加和细胞溶质游离 Ca 过载2+ (cCa 2+ ) 随着线粒体膜电位、细胞溶质 (cROS) 和线粒体 (mROS) ROS 的增加流入。在不存在 TRPM2 和 TRPV4 或存在 Ca 2+游离细胞外缓冲液和 PARP-1 抑制剂(PJ34 和 DPQ)的情况下未观察到这些变化。当 OS 诱导的 TRPM2 和 GSK 诱导的 TRPV4 活化被 CARV 处理抑制时,cROS、mROS、脂质过氧化、细胞凋亡、细胞死亡、cCa 2+浓度、caspase -3 和 caspase -9 水平的增加得到恢复通过上调谷胱甘肽和谷胱甘肽过氧化物酶。总之,CARV 的治疗调节了 TRPM2 和 TRPV4 介导的超载 Ca 2+流入并可能为保护与 mROS 和 cCa 2+增加相关的 TRPM2 和 TRPV4 介导的神经退行性疾病提供途径。
图形概要
香芹酚 (CARV) 可能通过调节 SH-SY5Y 神经元细胞中的氧化应激和细胞凋亡而发挥 TRPM2 和 TRPV4 阻滞剂作用。TRPM2 被 DNA 损伤诱导(通过 PARP-1 激活)ADP-核糖 (ADPR) 和活性氧 (ROS) (H 2 O 2 ) 激活,尽管它被非特异性抑制剂(ACA 和 2-APB)抑制。TRPV4 被 GSK1016790A (GSK) 处理激活,尽管它被非特异性抑制剂(钌红,RuRe)抑制。GSK 的治疗诱导过量产生 ROS。游离胞质 Ca 2+ (cCa 2+) 通过激活线粒体中的 TRPM2 和 TRPV4 导致线粒体膜去极化 (ΔΨm) 的增加。反过来,ΔΨm 的增加导致 ROS 的过度产生。TRPM2 和 TRPV4 诱导的过量生成的 ROS 通过激活神经元细胞中的半胱天冬酶 -3 (Casp-3) 和半胱天冬酶 -9 (Casp-9) 导致细胞凋亡和细胞死亡的增加,尽管它们的氧化作用降低谷胱甘肽 (GSH) 和谷胱甘肽过氧化物酶 (GSHPx) 水平。TRPM2 和 TRPV4 的氧化和凋亡不良作用受 CARV 处理的调节
"点击查看英文标题和摘要"
A novel antagonist of TRPM2 and TRPV4 channels: Carvacrol
The overload cytosolic free Ca2+ (cCa2+) influx-mediated excessive generation of oxidative stress in the pathophysiological conditions induces neuronal and cellular injury via the activation of cation channels. TRPM2 and TRPV4 channels are activated by oxidative stress, and their specific antagonists have not been discovered yet. The antioxidant and anti-Covid-19 properties of carvacrol (CARV) were recently reported. Hence, I suspected possible antagonist properties of CARV against oxidative stress (OS)/ADP-ribose (ADPR)-induced TRPM2 and GSK1016790A (GSK)-mediated TRPV4 activations in neuronal and kidney cells. I investigated the antagonist role of CARV on the activations of TRPM2 and TRPV4 in SH-SY5Y neuronal, BV-2 microglial, and HEK293 cells. The OS/ADPR and GSK in the cells caused to increase of TRPM2/TRPV4 current densities and overload cytosolic free Ca2+ (cCa2+) influx with an increase of mitochondrial membrane potential, cytosolic (cROS), and mitochondrial (mROS) ROS. The changes were not observed in the absence of TRPM2 and TRPV4 or the presence of Ca2+ free extracellular buffer and PARP-1 inhibitors (PJ34 and DPQ). When OS-induced TRPM2 and GSK-induced TRPV4 activations were inhibited by the treatment of CARV, the increase of cROS, mROS, lipid peroxidation, apoptosis, cell death, cCa2+ concentration, caspase -3, and caspase -9 levels were restored via upregulation of glutathione and glutathione peroxidase. In conclusion, the treatment of CARV modulated the TRPM2 and TRPV4-mediated overload Ca2+ influx and may provide an avenue for protecting TRPM2 and TRPV4-mediated neurodegenerative diseases associated with the increase of mROS and cCa2+.
Graphical abstract
The possible TRPM2 and TRPV4 blocker action of carvacrol (CARV) via the modulation oxidative stress and apoptosis in the SH-SY5Y neuronal cells. TRPM2 is activated by DNA damage-induced (via PARP-1 activation) ADP-ribose (ADPR) and reactive oxygen species (ROS) (H2O2), although it is inhibited by nonspecific inhibitors (ACA and 2-APB). TRPV4 is activated by the treatments of GSK1016790A (GSK), although it is inhibited by a nonspecific inhibitor (ruthenium red, RuRe). The treatment of GSK induces excessive generation of ROS. The accumulation of free cytosolic Ca2+ (cCa2+) via the activations of TRPM2 and TRPV4 in the mitochondria causes the increase of mitochondrial membrane depolarization (ΔΨm). In turn, the increase of ΔΨm causes the excessive generation of ROS. The TRPM2 and TRPV4-induced the excessive generations of ROS result in the increase of apoptosis and cell death via the activations of caspase -3 (Casp-3) and caspase -9 (Casp-9) in the neuronal cells, although their oxidant actions decrease the glutathione (GSH) and glutathione peroxidase (GSHPx) levels. The oxidant and apoptotic adverse actions of TRPM2 and TRPV4 are modulated by the treatment of CARV